The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...

Brokerages Motilal Oswal and Jefferies have maintained positive outlooks for ICICI Bank, Torrent Pharmaceuticals, and Godrej ...

The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year. The ...

Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs ...

Abbott also is a buy for its dividend strength. As a Dividend King it's raised its dividend for more than 50 consecutive ...

For the uninitiated, Recursion wants to become the go-to provider of AI-based drug discovery and development services for the ...

Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap ...

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

BioCryst Pharmaceuticals Inc (BCRX) stock saw a decline, ending the day at $7.64 which represents a decrease of $-0.09 or -1.16% from the prior close of $7.73. The stock opened at $7.64 and touched a ...